Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97T
+4.40%+2.06%+23.50%+15.62% 22TCr
+5.19%+2.52%-0.58%-15.67% 14TCr
+2.25%-0.16%-16.40%+39.75% 14TCr
+3.50%+1.53%-49.68%+3.54% 7.31TCr
+1.41%-0.84%+16.89%+20.88% 5.24TCr
+1.32%+2.43%-16.15%-12.09% 5.09TCr
+3.67%+4.35%+28.79%+30.15% 4.19TCr
+3.46%+0.30%+40.20%+56.24% 3.94TCr
+2.91%+3.51%+1.15%+8.48% 3.28TCr
Average +2.82%-1.97%+3.08%+16.32% 8.74TCr
Weighted average by Cap. +3.54%-2.40%+2.58%+14.23%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock